About STAAR Surgical Company (NASDAQ:STAA)
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). As of December 30, 2016, it sold its products in more than 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: Health Care Supplies
- Symbol: NASDAQ:STAA
- CUSIP: 85231230
- Web: www.staar.com
Capitalization:- Market Cap: $548.8 million
- Outstanding Shares: 41,108,000
Average Prices:- 50 Day Moving Avg: $12.26
- 200 Day Moving Avg: $10.67
- 52 Week Range: $7.45 - $13.95
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 71.32
- P/E Growth: -4.89
Sales & Book Value:- Annual Revenue: $84.48 million
- Price / Sales: 6.59
- Book Value: $0.93 per share
- Price / Book: 14.57
Profitability:- EBITDA: ($672,999.00)
- Net Margins: -6.06%
- Return on Equity: -8.69%
- Return on Assets: -5.03%
Debt:- Debt-to-Equity Ratio: 0.03%
- Current Ratio: 2.52%
- Quick Ratio: 1.81%
Misc:- Average Volume: 91,705 shs.
- Beta: 1.18
- Short Ratio: 31.08
Frequently Asked Questions for STAAR Surgical Company (NASDAQ:STAA)
What is STAAR Surgical Company's stock symbol?
STAAR Surgical Company trades on the NASDAQ under the ticker symbol "STAA."
How were STAAR Surgical Company's earnings last quarter?
STAAR Surgical Company (NASDAQ:STAA) issued its earnings results on Wednesday, August, 2nd. The company reported ($0.01) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.04. The firm had revenue of $21.90 million for the quarter, compared to analyst estimates of $22.15 million. STAAR Surgical Company had a negative return on equity of 8.69% and a negative net margin of 6.06%. The firm's revenue for the quarter was up 4.8% on a year-over-year basis. During the same period last year, the company earned ($0.02) earnings per share. View STAAR Surgical Company's Earnings History.
When will STAAR Surgical Company make its next earnings announcement?
Where is STAAR Surgical Company's stock going? Where will STAAR Surgical Company's stock price be in 2017?
2 analysts have issued 12-month price objectives for STAAR Surgical Company's shares. Their predictions range from $13.00 to $15.00. On average, they expect STAAR Surgical Company's share price to reach $14.00 in the next twelve months. View Analyst Ratings for STAAR Surgical Company.
Who are some of STAAR Surgical Company's key competitors?
Some companies that are related to STAAR Surgical Company include Cardiovascular Systems (CSII), Orthofix International N.V. (OFIX), Intersect ENT (XENT), K2M Group Holdings (KTWO), AtriCure (ATRC), CryoLife (CRY), Landauer (LDR), Meridian Bioscience (VIVO), Consort Medical plc (CSRT), Invacare (IVC), Exactech (EXAC), Transenterix (TRXC), Transenterix (TRXC), Antares Pharma (ATRS), Sientra (SIEN), Utah Medical Products (UTMD), Ocular Therapeutix (OCUL) and T2 Biosystems (TTOO).
Who are STAAR Surgical Company's key executives?
STAAR Surgical Company's management team includes the folowing people:
- Caren L. Mason, President, Chief Executive Officer, Director
- Deborah J. Andrews, Vice President, Interim Chief Financial Officer
- Hans-Martin Blickensdoerfer, Senior Vice President - Commercial Operations for Europe, Middle East, Africa, Latin America and China.
- James E. Francese, Senior Vice President of North American and APAC
- Keith Holliday Ph.D., Chief Technology Officer, Vice President
- William Walter Goodmen, Vice President - Global Human Resources
- Jon K. Hayashida, Vice President - Global Clinical and Medical Affairs
- Philippe Subrin, Vice President-ICL Manufacturing
- Samuel J. Gesten, Vice President - Business Development, Chief Legal Officer and Secretary
- Denise McEachern, Global Head of Regulatory Affairs and Quality Assurance
How do I buy STAAR Surgical Company stock?
Shares of STAAR Surgical Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is STAAR Surgical Company's stock price today?
One share of STAAR Surgical Company stock can currently be purchased for approximately $13.55.
MarketBeat Community Rating for STAAR Surgical Company (NASDAQ STAA)MarketBeat's community ratings are surveys of what our community members think about STAAR Surgical Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for STAAR Surgical Company (NASDAQ:STAA)Earnings History by Quarter for STAAR Surgical Company (NASDAQ STAA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | ($0.04) | | | | | N/A |  |
| 8/2/2017 | Q2 2017 | ($0.05) | ($0.01) | $22.15 million | $21.90 million | View | Listen | |
| 5/3/2017 | Q1 2017 | ($0.05) | ($0.05) | | $20.35 million | View | Listen | |
| 3/2/2017 | Q4 2016 | ($0.02) | $0.02 | $22.25 million | $22.10 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.04) | ($0.02) | $20.70 million | $20.05 million | View | Listen | |
| 8/3/2016 | Q216 | ($0.05) | ($0.05) | $19.88 million | $21.00 million | View | Listen | |
| 5/11/2016 | Q116 | ($0.17) | ($0.01) | $19.60 million | $19.30 million | View | Listen | |
| 3/2/2016 | Q415 | ($0.02) | $0.01 | $19.11 million | $20.90 million | View | Listen | |
| 10/28/2015 | Q315 | ($0.04) | ($0.04) | $17.87 million | $18.80 million | View | Listen | |
| 4/29/2015 | Q115 | ($0.04) | $0.03 | $17.85 million | $18.90 million | View | Listen | |
| 2/25/2015 | Q414 | ($0.05) | ($0.03) | $16.60 million | $16.60 million | View | Listen | |
| 10/30/2014 | Q314 | $0.02 | ($0.04) | $19.53 million | $18.20 million | View | Listen | |
| 7/30/2014 | Q214 | $0.03 | $0.01 | $19.80 million | $20.05 million | View | Listen | |
| 4/28/2014 | Q114 | $0.01 | $0.04 | $19.44 million | $20.20 million | View | Listen | |
| 2/26/2014 | Q413 | $0.02 | $0.02 | $18.98 million | $18.90 million | View | Listen | |
| 10/30/2013 | Q313 | $0.02 | $0.04 | $17.35 million | $17.10 million | View | Listen | |
| 7/31/2013 | Q2 2013 | $0.04 | $0.05 | $17.40 million | $18.20 million | View | Listen | |
| 5/1/2013 | Q1 2013 | $0.04 | $0.08 | $17.27 million | $18.00 million | View | Listen | |
| 2/27/2013 | Q4 2012 | $0.03 | $0.01 | $17.55 million | $16.50 million | View | Listen | |
| 10/31/2012 | Q312 | $0.01 | $0.04 | $16.78 million | $15.90 million | View | N/A | |
| 8/1/2012 | | $0.03 | $0.03 | | | View | N/A | |
| 5/2/2012 | | $0.03 | $0.04 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for STAAR Surgical Company (NASDAQ:STAA)Current Year EPS Consensus Estimate: $-0.03 EPS
Next Year EPS Consensus Estimate: $0.19 EPS
Dividend History for STAAR Surgical Company (NASDAQ:STAA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for STAAR Surgical Company (NASDAQ:STAA)Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 76.54%
Insider Trades by Quarter for STAAR Surgical Company (NASDAQ:STAA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/9/2016 | Hans-Martin Blickensdoerfer | VP | Sell | 25,000 | $11.14 | $278,500.00 | |
| 6/29/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 14,144 | $5.24 | $74,114.56 | |
| 5/25/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 77,842 | $5.16 | $401,664.72 | |
| 5/24/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 70,000 | $5.16 | $361,200.00 | |
| 5/23/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 3,138 | $5.24 | $16,443.12 | |
| 5/20/2016 | Richard A Meier | Director | Sell | 25,000 | $5.35 | $133,750.00 | |
| 5/17/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 9,313 | $5.23 | $48,706.99 | |
| 5/16/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 336,210 | $5.49 | $1,845,792.90 | |
| 2/9/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 91,770 | $6.25 | $573,562.50 | |
| 2/3/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 121,599 | $6.40 | $778,233.60 | |
| 2/1/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 65,983 | $6.48 | $427,569.84 | |
| 1/27/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 239,013 | $6.63 | $1,584,656.19 | |
| 1/26/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 112,900 | $6.60 | $745,140.00 | |
| 1/25/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 81,752 | $6.74 | $551,008.48 | |
| 1/20/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 72,858 | $6.75 | $491,791.50 | |
| 1/15/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 135,725 | $6.73 | $913,429.25 | |
| 1/11/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 86,586 | $6.83 | $591,382.38 | |
| 1/7/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 267,047 | $6.95 | $1,855,976.65 | |
| 1/4/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 165,461 | $7.11 | $1,176,427.71 | |
| 9/29/2015 | Broadwood Partners Lp | Major Shareholder | Buy | 311,099 | $7.08 | $2,202,580.92 | |
| 8/25/2015 | Broadwood Partners Lp | Major Shareholder | Buy | 188,881 | $7.17 | $1,354,276.77 | |
| 8/24/2015 | Caren L Mason | CEO | Buy | 10,000 | $7.34 | $73,400.00 | |
| 4/6/2015 | Samuel J Gesten | VP | Sell | 3,223 | $7.14 | $23,012.22 | |
| 3/3/2015 | Robin Hughes | VP | Sell | 23,253 | $15.82 | $367,862.46 | |
| 11/19/2014 | Broadwood Partners Lp | Major Shareholder | Buy | 189,646 | $8.64 | $1,638,541.44 | |
| 11/18/2014 | Broadwood Partners Lp | Major Shareholder | Buy | 39,400 | $8.67 | $341,598.00 | |
| 11/17/2014 | Broadwood Partners Lp | Major Shareholder | Buy | 118,200 | $8.63 | $1,020,066.00 | |
| 11/10/2014 | Broadwood Partners Lp | Major Shareholder | Buy | 500 | $8.79 | $4,395.00 | |
| 11/7/2014 | Broadwood Partners Lp | Major Shareholder | Buy | 80,000 | $8.92 | $713,600.00 | |
| 11/4/2014 | Broadwood Partners Lp | Major Shareholder | Buy | 260,341 | $9.20 | $2,395,137.20 | |
| 5/15/2014 | John Moore | Director | Sell | 2,800 | $14.87 | $41,636.00 | |
| 3/19/2014 | James Francese | VP | Sell | 16,666 | $17.22 | $286,988.52 | |
| 3/17/2014 | Robin Hughes | VP | Sell | 5,672 | $16.61 | $94,211.92 | |
| 9/4/2013 | Deborah Andrews | CFO | Sell | 50,000 | $12.88 | $644,000.00 | |
| 8/20/2013 | Deborah Andrews | CFO | Sell | 33,515 | $11.65 | $390,449.75 | |
| 8/12/2013 | Deborah Andrews | CFO | Sell | 9,079 | $11.62 | $105,497.98 | |
| 8/7/2013 | Deborah Andrews | CFO | Sell | 11,721 | $11.79 | $138,190.59 | |
| 5/9/2013 | Deborah J Andrews | CFO | Sell | 5,000 | $8.96 | $44,800.00 | |
| 12/11/2012 | John C Moore | Director | Buy | 5,000 | $5.46 | $27,300.00 | |
| 11/15/2012 | Broadwood Partners Lp | Major Shareholder | Buy | 2,618 | $5.00 | $13,090.00 | |
| 11/15/2012 | Mark B Logan | Director | Buy | 3,600 | $5.22 | $18,792.00 | |
| 11/14/2012 | Barry G Caldwell | CEO | Buy | 5,000 | $5.04 | $25,200.00 | |
| 11/2/2012 | Broadwood Partners Lp | Major Shareholder | Buy | 22,572 | $5.00 | $112,860.00 | |
| 8/9/2012 | Barry G Caldwell | CEO | Buy | 5,000 | $6.57 | $32,850.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for STAAR Surgical Company (NASDAQ:STAA)
Latest Headlines for STAAR Surgical Company (NASDAQ:STAA)
| Source: |
|
| Date | Headline |
|---|
 | Zacks Investment Research Lowers STAAR Surgical Company (STAA) to Hold
www.americanbankingnews.com - October 11 at 8:28 PM |
 | Short Interest Declines 16.4% For STAA
www.thestreet.com - October 11 at 3:27 PM |
| $0.02 Earnings Per Share Expected for STAAR Surgical Company (STAA) This Quarter
www.americanbankingnews.com - October 11 at 2:16 PM |
| Canaccord Genuity Reaffirms Buy Rating for STAAR Surgical Company (STAA)
www.americanbankingnews.com - October 9 at 2:34 PM |
| STAAR Surgical (STAA) & The Competition Head-To-Head Review
www.americanbankingnews.com - October 7 at 12:18 AM |
 | STAAR Surgical Appoints Scott D. Barnes, M.D. as Chief Medical Officer
finance.yahoo.com - October 3 at 12:59 PM |
| STAAR Surgical (STAA) versus Haemonetics Corporation (HAE) Critical Comparison
www.americanbankingnews.com - October 2 at 12:22 AM |
 | STAAR Surgical Names Deborah Andrews as CFO - PR Newswire (press release)
www.prnewswire.com - September 29 at 7:46 AM |
| DexCom (DXCM) vs. STAAR Surgical (STAA) Head-To-Head Analysis
www.americanbankingnews.com - September 28 at 2:28 PM |
 | STAAR Surgical Names Deborah Andrews as CFO
www.bizjournals.com - September 28 at 12:05 PM |
| STAAR Surgical Company (STAA) Upgraded to "Buy" by Canaccord Genuity
www.americanbankingnews.com - September 26 at 12:28 AM |
| ETFs with exposure to STAAR Surgical Co. : September 22, 2017
finance.yahoo.com - September 23 at 8:48 AM |
| STAAR Surgical (STAA) & Bio-Rad Laboratories (BIO) Head-To-Head Contrast
www.americanbankingnews.com - September 16 at 4:42 AM |
| STAAR Surgical (STAA) & The Competition Head to Head Review
www.americanbankingnews.com - September 12 at 12:28 AM |
| STAAR Surgical Company (STAA) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - September 10 at 10:10 PM |
| InspireMD (NSPR) & STAAR Surgical (STAA) Head to Head Comparison
www.americanbankingnews.com - September 7 at 4:28 AM |
| TheStreet Upgrades STAAR Surgical Company (STAA) to C
www.americanbankingnews.com - August 17 at 12:26 PM |
| Corporate News Blog - STAAR Surgical Announces Strategic Cooperation Agreement with Seoul/Busan Eye Clinic
finance.yahoo.com - August 17 at 7:58 AM |
| STAAR Surgical and Seoul/Busan BalGeunSeSang Eye Clinic Announce Strategic Cooperation Agreement
finance.yahoo.com - August 15 at 7:22 AM |
| STAAR Surgical Company (NASDAQ:STAA) Price Target Raised to $13.00 at Benchmark Co.
www.americanbankingnews.com - August 14 at 8:36 AM |
| Brokerages Set $11.67 Target Price for STAAR Surgical Company (STAA)
www.americanbankingnews.com - August 11 at 11:14 PM |
| STAAR Surgical (STAA) versus OraSure Technologies (OSUR) Head-To-Head Comparison
www.americanbankingnews.com - August 6 at 2:22 PM |
| STAAR Surgical Company (NASDAQ:STAA) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - August 3 at 9:21 PM |
| STAAR Surgical Company (NASDAQ:STAA) Price Target Increased to $11.00 by Analysts at Canaccord Genuity
www.americanbankingnews.com - August 3 at 6:06 PM |
 | STAAR's (STAA) CEO Caren Mason on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 3 at 7:34 AM |
 | EARNINGS SUMMARY: Details of STAAR Surgical Company Q2 Earnings Report
www.rttnews.com - August 3 at 7:34 AM |
| STAAR Surgical Reports Second Quarter 2017 Results
finance.yahoo.com - August 3 at 7:34 AM |
| Edited Transcript of STAA earnings conference call or presentation 2-Aug-17 8:30pm GMT
finance.yahoo.com - August 3 at 7:34 AM |
| Staar Surgical reports 2Q loss
finance.yahoo.com - August 3 at 7:34 AM |
| Critical Comparison: STAAR Surgical (STAA) versus OraSure Technologies (OSUR)
www.americanbankingnews.com - July 31 at 9:32 AM |
| STAAR Surgical Company (STAA) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 27 at 4:09 PM |
| STAAR Surgical to Report Second Quarter Results on August 2, 2017
finance.yahoo.com - July 20 at 8:08 AM |
 | Staar Surgical to pay $7 million in investor suit over FDA violations
www.reuters.com - June 22 at 1:50 PM |
| EARNINGS SUMMARY: Details of STAAR Surgical Company Q1 Earnings Report
www.rttnews.com - May 3 at 6:12 PM |
| BRIEF-Staar Surgical reports Q1 sales $20.4 million
www.reuters.com - May 3 at 6:12 PM |
 | CFO Moves: Varian Medical Systems, STAAR Surgical, Federated National Holding, Daily Mail & General Trust
blogs.wsj.com - April 7 at 12:48 PM |
| STAAR SURGICAL CO Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - March 3 at 8:01 PM |
| STAAR Surgical's (STAA) CEO Caren Mason on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 2 at 8:08 PM |
 | STAAR Surgical Company Q4 Income Climbs 46%
www.nasdaq.com - March 2 at 8:08 PM |
| BRIEF-Staar Surgical Q4 adjusted earnings per share $0.02
www.reuters.com - March 2 at 8:08 PM |
| Q4 2016 STAAR Surgical Co Earnings Release - After Market Close
us.rd.yahoo.com - March 2 at 8:08 PM |
 | STAAR Surgical Reports Fourth Quarter 2016 Results
us.rd.yahoo.com - March 2 at 8:08 PM |
| 4:04 pm STAAR Surgical reports EPS in-line, revs in-line
us.rd.yahoo.com - March 2 at 8:08 PM |
| STAAR SURGICAL CO Files SEC form 8-K, Results of Operations and Financial Condition
us.rd.yahoo.com - March 2 at 8:08 PM |
 | North America Ophthalmology Cataract Surgery Devices Market - Opportunities and Forecasts, 2014 - 2022 - Research and Markets
www.businesswire.com - February 22 at 10:05 AM |
 | Form 8-K STAAR SURGICAL CO For: Jan 10
www.streetinsider.com - January 12 at 1:24 AM |
STAAR Surgical Company (STAA) Chart for Tuesday, October, 17, 2017
